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Introduction: The	major	 complication	 of	 protein	 replacement	 therapy	 for	 haemo-
philia	 A	 is	 the	 development	 of	 anti‐FVIII	 antibodies	 or	 inhibitors	 that	 occur	 in	
25%‐30%	of	persons	with	 severe	haemophilia	A.	Alternative	 therapeutics	 such	as	
bypassing	agents	or	immune	tolerance	induction	protocols	have	additional	challenges	
and	are	not	always	effective.
Aim: Assemble	 a	 National	 Heart,	 Lung	 and	 Blood	 Institute	 (NHLBI)	 State	 of	 the	
Science	(SOS)	Workshop	to	generate	a	national	blueprint	for	research	on	inhibitors	to	
solve	the	problem	of	FVIII	immunogenicity.
Methods: An	Executive	Steering	Committee	was	formed	in	October	2017	to	estab-
lish	the	scientific	focus	and	Scientific	Working	Groups	for	the	SOS	Workshop	in	May	
2018.	Four	working	groups	were	assembled	to	address	scientific	priorities	in	basic,	
translational	and	clinical	research	on	inhibitors.
Results: Working	Group	1	was	charged	with	determining	the	scientific	priorities	for	
clinical	trials	to	include	the	integration	of	non‐intravenous,	non‐factor	therapeutics	
including	gene	therapy	into	the	standard	of	care	for	people	with	haemophilia	A	with	
inhibitors.	Working	Group	2	established	the	scientific	priorities	for	21st‐century	data	
science	and	biospecimen	collection	 for	observational	 inhibitor	cohort	 studies.	The	
scientific	priorities	for	acquiring	an	actionable	understanding	of	FVIII	immunogenic-
ity	and	the	immunology	of	the	host	response	and	FVIII	tolerance	were	developed	by	
Working	Group	3.	Working	Group	4	designed	prospective	pregnancy/birth	cohorts	
to	study	FVIII	immunogenicity,	inhibitor	development	and	eradication.
Conclusion: The	NHLBI	SOS	Workshop	generated	a	focused	summary	of	scientific	
priorities	and	implementation	strategies	to	overcome	the	challenges	of	eradicating	
and	preventing	inhibitors	in	haemophilia	A.
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1  | INTRODUC TION: HAEMOPHILIA AND 
THE DE VELOPMENT OF INHIBITORS TO 
FAC TOR VII I
Haemophilia	A	is	an	X‐linked	bleeding	disorder	that	is	due	to	a	defi-
ciency	in	coagulation	factor	VIII	(FVIII).	Haemophilia	occurs	in	about	
1	in	5000	male	births,	80%	of	whom	are	affected	with	haemophilia	A	
which	translates	to	approximately	16	000	persons	with	haemophilia	
A	(PWHA)	in	the	United	States.1	PWHA	with	the	severe	form	of	the	
disorder	(<1%	of	normal	plasma	FVIII	activity)	present	with	frequent	
spontaneous	bleeding	episodes	that	occur	primarily	in	the	joints	and	
soft	tissues.2
The	 current	 treatment	 for	 haemophilia	 is	 protein	 replacement	
therapy	with	plasma‐derived	or	recombinant	factor	VIII	proteins	that	
are	given	on‐demand	in	response	to	bleeds	or	prophylactically	with	
the	 goal	 of	 preventing	bleeding	 episodes.3	While	 this	 therapy	has	
transformed	the	care	of	PWHA,	the	major	complication	of	replace-
ment	 therapy	 is	 the	 development	 of	 neutralizing	 alloantibodies	 to	
the	FVIII	protein,	termed	inhibitors,	which	at	high	titre	(≥5	Bethesda	
Units)	render	the	therapy	ineffective.4	This	is	most	significant	in	se-
vere	haemophilia	A	where	25%‐30%	of	people	develop	clinically	sig-
nificant	anti‐FVIII	antibodies	at	a	median	age	of	15	months	and	after	
a	median	of	14	exposures	to	factor	VIII.5,6	 Importantly,	the	impact	
of	inhibitors	on	the	patient	is	significant	with	more	frequent	hemar-
throses,	more	severe	arthropathy,	a	 reduced	quality	of	 life	and	an	
increased	risk	of	death.7-9
Both	genetic	 and	environmental	 risk	 factors	have	been	asso-
ciated	with	inhibitor	development.5,6	Genetic	factors	may	include	
the	FVIII	mutation,	the	severity	of	the	haemophilia,	family	history	
of	 inhibitors,	 ethnicity	 and	 polymorphisms	 of	 immune	 response	
genes.	 Environmental	 factors	 may	 include	 the	 FVIII	 product	
(plasma‐derived	vs	recombinant),	 intensity	of	FVIII	exposure,	age	
at	the	start	of	treatment	and	events	such	as	infection,	inflammation	
and	 surgery.	However,	 an	 incomplete	mechanistic	understanding	
of	risk	factors	interpreted	through	informative	immune	biomarkers	
limits	the	ability	to	both	accurately	predict	inhibitor	development	
in	an	individual	child	with	severe	haemophilia	A	and	intervene	with	
timely	inhibitor	prevention	or	eradication	strategies.10
The	development	of	inhibitors	to	FVIII	results	in	the	neutraliza-
tion	 or	 rapid	 clearance	 of	 the	 FVIII	 protein	 that	 renders	 the	 FVIII	
therapy	ineffective.	Until	recently,	the	mainstay	therapy	for	bleeding	
in	the	presence	of	an	inhibitor	has	been	the	use	of	bypassing	agents,	
activated	prothrombin	complex	concentrates11	or	recombinant	fac-
tor	VIIa,12	to	achieve	haemostasis.	These	treatments	are	associated	
with	 additional	 challenges	 including	 reduced	 efficacy	 in	 the	 treat-
ment	or	prevention	of	haemorrhage	compared	to	FVIII	products	in	
those	without	an	inhibitor	and	the	inability	to	accurately	predict	the	
bleeding	 response.13-15	 An	 alternative	 approach	 for	 treating	 these	
patients	is	to	attempt	to	induce	immune	tolerance	to	the	FVIII	pro-
tein	 through	 immune	 tolerance	 induction	 (ITI)	 protocols.16	 Several	
ITI	regimens	have	been	developed	that	use	a	range	of	FVIII	dosing	
regimens,	 occasionally	 accompanied	 by	 immunomodulation.17,18 
However,	 the	 studies	 have	 not	 yielded	 a	 consensus	 on	 a	 practice	
approach	for	ITI	in	part	due	to	the	number	of	factors	that	influence	
the	success	of	ITI.	In	addition,	the	economic	burden	of	this	treatment	
is	 significant	 since	 the	 annual	 cost	 in	 the	United	 States	 increases	
between	 $150	000	 and	 $200	000	 without	 inhibitors	 to	 almost	
$1	000	000	with	an	inhibitor.19
Novel	 non‐factor	 therapeutics	 to	 treat	 haemophilia	 in	 the	
presence	of	 inhibitors	are	on	the	horizon.20-22	Emicizumab,	a	hu-
manized	bispecific	monoclonal	antibody	that	mimics	the	function	
of	 FVIII,	 has	 recently	 been	 approved	 for	 use	 in	 PWHA	 with	 or	
without	 FVIII	 inhibitors.20,23	 Gene	 therapy	 approaches	 are	 also	
in	clinical	development	with	phase	 III	clinical	 trials	underway	for	
PWHA	without	 inhibitors.24	This	single	dose	 treatment	may	also	
provide	a	promising	new	treatment	for	PWHA	and	inhibitors	that	
have	the	potential	to	be	a	lifelong	therapy.	While	these	new	ther-
apies	may	change	the	approach	to	treating	patients,	national	and	
international	 data	 gathered	 from	 harmonized	 and	 standardized	
observational	cohorts	and	innovatively	designed	clinical	trials	will	
be	required	to	integrate	them	into	the	standard	of	care	for	PWHA	
with	inhibitors.25,26
2  | ORIGINS OF THE STATE OF THE 
SCIENCE WORKSHOP
Within	the	United	States,	it	is	estimated	that	there	are	at	least	1000	
individuals	with	 a	 factor	VIII	 inhibitor.27	 The	Centers	 for	Disease	
Control	and	Prevention	(CDC)’s	Division	of	Blood	Disorders	(DBD)	
have	 been	 committed	 to	 the	 goal	 of	 reducing	 the	 occurrence	 of	
inhibitors,	 the	 most	 significant	 and	 costly	 complication	 affecting	
persons	 with	 haemophilia	 today.	 Following	 a	 multi‐stakeholder	
summit	 in	 2012,	 the	 CDC	 facilitated	 a	 national	 integrated	 inhibi-
tor	surveillance	programme	through	a	cooperative	agreement	with	
the	US	Hemophilia	Treatment	Center	Network	(USHTCN)	and	the	
American	Thrombosis	and	Hemostasis	Network	(ATHN)	to	collect	
information	about	key	aspects	of	inhibitor	development,	treatment	
and	outcomes	and	established	 the	DBD	Reference	Laboratory	 to	
develop	 the	 methodology	 required	 for	 centralized	 sensitive	 and	
specific	 inhibitor	 testing.28	A	 second	multi‐stakeholder	 summit	 in	
2017	included	an	objective	to	explore	the	need	for	a	national,	pri-
oritized	 inhibitor	 scientific	 agenda	 and	 the	 blueprint	 for	 its	 coor-
dinated	 implementation.	The	 rationale	 for	 this	 coordinated	effort	
included:
•	 Subjects	needed	for	studies	in	this	area	(primarily	previously	un-
treated	patients)	are	a	precious	 resource,	and	efforts	should	be	
made	to	coordinate	studies	so	that	the	maximum	benefit	can	be	
obtained	from	each	study	subject.
•	 Oversight	 is	needed	to	assure	that	only	the	most	promising	sci-
ence	is	performed	and	funding	for	the	studies	should	be	adequate	
to	cover	the	costs	of	obtaining	high‐quality	data.
•	 Multifaceted	education	 and	 informational	 activities	must	 be	di-
rected	to	the	patient	community	well	in	advance	of	upcoming	tri-
als	and	are	required	to	stimulate	interest	and	participation.
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•	 Development	of	a	multidisciplinary	group	is	required	to	develop	
and	implement	an	integrated	scientific	and	public	health	agenda	
as	well	as	to	establish	the	infrastructure	within	which	the	essen-
tial	science	can	be	conducted.
•	 Representatives	from	a	wide	variety	of	disciplines	should	be	 in-
cluded	to	facilitate	the	generation	of	new	ideas	and	approaches.
•	 Agreement	 from	 the	 bleeding	 disorder	 community	 to	 proceed	
with	regimented,	cooperative,	appropriately	vetted	studies	must	
be	secured.
Following	this	CDC	summit,	the	Medical	and	Scientific	Advisory	
Council	 (MASAC)	to	the	National	Hemophilia	Foundation	formed	
the	MASAC	Inhibitor	Prevention	and	Eradication	Working	Group	
in	March	2017	with	a	charter	that	 included	a	mandate	to	engage	
the	haemophilia	community	in	the	development	of	a	national	sci-
entific	agenda	that	would	ensure	the	coordinated	future	conduct	
of	the	most	efficient	and	impactful	research.	The	MASAC	Inhibitor	
Prevention	and	Eradication	Working	Group,	 in	collaboration	with	
the	 Division	 of	 Blood	 Diseases	 and	 Resources	 of	 the	 National	
Heart	 Lung	 and	 Blood	 Institute	 (NHLBI)/National	 Institutes	 of	
Health	 (NIH),	developed	the	concept	for	The	NHLBI	State	of	 the	
Science	(SOS)	Workshop.	The	goal	of	the	workshop	was	to	solicit	
input	 from	 the	 haemophilia	 community	 as	 well	 as	 from	 experts	
from	 outside	 the	 field	 into	 the	 development	 of	 a	 coordinated	
US‐based	blueprint	 for	 future	basic,	 translational	 and	 clinical	 re-
search	 focused	on	FVIII	 immunogenicity	and	 factor	VIII	 inhibitor	
prevention/eradication.
3  | ORGANIZ ATION OF THE STATE OF 
THE SCIENCE WORKSHOP
The	efforts	to	assemble	the	SOS	Workshop	began	in	October	2017.	
The	Executive	Steering	Committee,	constituted	by	the	authors	of	
this	manuscript,	was	established	and	given	the	mandate	to	estab-
lish	the	scientific	focus	for	as	well	as	the	leadership	and	member-
ship	 of	 the	 Scientific	 Working	 Groups,	 to	 oversee	 the	 pre‐SOS	
Working	Group	deliberations	 and	 to	 develop	 the	 SOS	Workshop	
agenda.	Four	 scientific	priorities	were	 identified	across	 the	spec-
trum	of	basic,	translational	and	clinical	research,	and	the	working	
groups	were	 organized	 around	 these	 specific	 topics	 (Tables	 1‐4).	
Working	group	members	were	deliberately	assembled	(1)	to	ensure	
that	diverse	perspectives	from	across	the	national	and	international	
haemophilia	 community	 informed	each	working	group's	delibera-
tions,	and	(2)	to	maximally	stimulate	scientific	thought	beyond	the	
current	 principles	 and	 approaches	 with	 relevant	 complimentary	
Co‐chairs Margaret	Ragni,	MD,	MPH	and	Lindsey	George,	MD
Charge The	design	of	investigator‐initiated	clinical	trials	to	determine	optimal	integration	
of	non‐IV,	non‐factor	therapeutics,	including	gene	therapy,	into	the	standard	of	
care	for	FVIII	inhibitor	patients
Goals •	 Overcome	the	challenges	associated	with	conducting	small	clinical	trials	in	rare	
diseases;	resources	and	partnerships	required	to	facilitate	them
•	 Leverage	the	HTC	infrastructure
•	 Potential	for	the	CDC	surveillance	databases	and	central	laboratory	to	serve	as	
a	platform	for	launching	prospective	clinical	trials
•	 Optimization	of	private‐public	partnerships	to	fund	clinical	trials
•	 Engage	the	patient	community	in	clinical	trials
•	 Embed	training	opportunities	within	the	implementation	strategy	for	clinical	
trials
TA B L E  1  Working	Group	1:	scientific	
priorities	and	innovative	implementation	
strategies	for	FVIII	inhibitor	clinical	trials
Co‐chairs Barbara	Konkle,	MD	and	Mike	Recht,	MD,	PhD
Charge The	design	of	and	supportive	infrastructure	for	prospective	longitudinal	cohorts	
to	ascertain	comparative	short	and	medium‐term	outcomes	from	the	incorpora-
tion,	or	not,	of	non‐intravenous,	non‐factor	novel	therapeutics,	including	gene	
therapy,	into	the	standard	of	care	for	FVIII	inhibitors
Goals •	 Incorporation	of	standard	measures	for	prioritized	outcomes
•	 Incorporation	of	patient‐reported	outcomes	(PROs)
•	 Models	for	direct	data	transfer	from	electronic	medical	records	(EMRs)
•	 Potential	for	the	CDC	surveillance	databases	and	central	laboratory	to	serve	as	
a	platform	for	launching	prospective	clinical	trials
•	 Streamlined	data	sharing	policies	for	individual	patient	level	data
•	 Challenges	associated	with	developing	and	maintaining	data	repositories	and	
biobanks	in	rare	diseases;	resources	and	partnerships	required	to	facilitate	and	
maintain	these	repositories
•	 Optimizing	private‐public	partnerships	to	fund	clinical	research
•	 Engage	the	patient	community	in	observational	cohort	studies
•	 Training	opportunities	in	epidemiology	and	data	science
TA B L E  2  Working	Group	2:	scientific	
priorities	and	strategies	for	21st‐century	
data	and	specimen	collection	and	
observational	FVIII	inhibitor	cohort	
studies
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expertise	 from	 outside	 the	 field	 (Tables	 S1‐S4).	 Expertise	 from	
broad	 scientific	 areas	was	 assembled	 to	 include	FVIII	 biochemis-
try,	 immunology,	 “omics,”	 gene	 therapy,	maternal	 and	 foetal	biol-
ogy,	epidemiology,	and	computational	biology.	The	working	groups	
also	brought	together	extensive	knowledge	in	clinical	trial	design,	
biostatistics,	 human	 subjects	 research,	 biobanking,	 data	 sharing	
and	ethics.	The	pharmaceutical	industry	was	represented	on	each	
working	 group.	 The	 haemophilia	 community	was	 represented	 by	
PWH,	patient	 advocacy	groups	 and	members	of	 the	haemophilia	
treatment	 centres	 (HTC).	 Financial	 conflicts	 of	 interest	were	 de-
clared	to	the	Working	Group	Chairs,	as	well	as	to	the	NHLBI,	and	
were	presented	at	the	SOS	Workshop.
Once	 the	 working	 groups	 were	 formed,	 their	 deliberations	
began	 in	 January	 2018	 and	 continued	 in	 the	 form	 of	 bi‐weekly	
discussions	 to	 determine	 the	 scientific	 priorities	 in	 each	 area.	
In	 addition,	 there	 was	 significant	 crosstalk	 among	 the	 working	
groups.	On	15	and	16	May	2018,	the	culmination	of	these	efforts	
was	presented	as	a	draft	of	research	priorities	and	implementation	
strategies	 from	 each	 working	 group	 at	 the	 NHLBI	 State	 of	 the	
Science	Workshop	 on	 FVIII	 Inhibitors	 at	 the	 National	 Institutes	
of	Health	in	Bethesda,	MD.	Input	from	the	wider	community	was	
solicited	through	both	plenary	and	working	group‐specific	break-
out	session	discussions.	Keynote	speakers	selected	from	outside	
the	 haemophilia	 community	 provided	 insights	 on	 topics	 related	
to	each	of	the	four	working	group	scientific	priorities.	These	top-
ics	 included	clinical	 trial	design	 in	 the	age	of	personalized	medi-
cine	 (Nicholas	 Schork,	 PhD,	 J.	 Craig	 Venter	 Institute,	 University	
of	California,	San	Diego),	 learning	health	systems	 for	assembling	
clinical	 research	 data	 (Charles	 Bailey,	 MD,	 PhD,	 The	 Children's	
Hospital	 of	 Philadelphia),	 the	 development	 of	 patient	 registries	
and	 cohorts	 in	 rare	 diseases	 (Jennifer	Mulle,	 PhD,	MHS,	 Emory	
University)	 and	 the	 use	 of	 the	 knowledge	 of	 immune	 pathways	
to	 reduce	protein	 immunogenicity	 (Elizabeth	Mellins,	MD,	Lucile	
Salter	Packard	Children's	Hospital,	Stanford	University).	The	2‐day	
workshop	was	 attended	by	more	 than	200	participants	 from	29	
states	and	nine	countries:	54%	represented	academia	and	HTCs;	
Co‐chairs Shannon	Meeks,	MD	and	Roland	Herzog,	PhD
Charge Basic	and	translational	research	to	elucidate	an	actionable	understanding	of	FVIII	
immunogenicity	and	the	immunology	of	both	the	host	immune	response	and	
tolerance	to	inform	predictive	models	for	inhibitor	development	and	novel	
therapeutic	targets
Goals •	 Application	of	novel	ideas,	technologies	and	cross‐disciplinary	science	to	these	
studies
•	 Consideration	of	the	role	of	host	cell	expression	of	FVIII/VWF	in	immuno-
genicity	as	well	as	gene	therapy	as	a	model	for	FVIII	immune	tolerance
•	 Identification	of	appropriate	animal	and	ex	vivo	models	for	immunogen	
expression	and	peptide	generation
•	 Human	biospecimens	required	to	further	research
•	 Challenges	associated	with	and	successful	models	for	conducting	cross‐disci-
plinary	science	as	well	as	resources	and	partners	required	for	success
•	 Optimization	of	private‐public	partnerships	in	basic/translational	research
•	 Training	models	and	opportunities	engendered	by	novel	cross‐disciplinary	
science
TA B L E  3  Working	Group	3:	scientific	
priorities	and	implementation	strategies	
for	acquiring	an	actionable	understanding	
of	FVIII	immunogenicity	and	the	
immunology	of	both	the	host	immune	
response	and	tolerance
Co‐chairs Deborah	Brown,	MD	and	Jill	Johnsen,	MD
Charge The	design	of	prospective	pregnancy/birth	longitudinal	cohorts	that	leverage	
multi‐“omics”	science,	existing	phenotypic	data	and	in	silico	protein	modelling	to	
study	FVIII	immunogenicity,	inhibitor	development	and	eradication
Goals •	 Design	data	capture	and	mechanistic	studies,	based	on	translational	scientific	
priorities	required	to	build	precision	(personalized)	medicine‐based
•	 Clinical	decision‐making	algorithms	that	can	be	applied	across	the	lifespan	to	
either	avoid	or	provoke	clinical	phenotype	for	the	purpose	of	diagnosis	and/or	
appropriate	time‐sensitive	intervention,	include	the	design	of	potential	
antenatal/neonatal	interventions
•	 Address	challenges	associated	with,	and	successful	models	for	building	
lifespan/intergenerational	cohorts,	as	well	as	resources	and	partners	required
•	 For	success,	including	unique	challenges	in	sample	procurement	and	banking
•	 Optimization	of	private‐public	partnerships	to	fund	longitudinal	cohorts
•	 Engage	the	patient	community	in	longitudinal	cohort	participation
•	 Training	models	and	opportunities	engendered	by	novel	cross‐disciplinary	
science
TA B L E  4  Working	Group	4:	design	of	
pregnancy/birth	longitudinal	cohorts	that	
leverage	'omics',	existing	phenotypic	data,	
and	in	silico	modelling	to	study	FVIII	
immunogenicity,	as	well	as	inhibitor	
development	and	eradication
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18%	were	scientists	from	the	federal	government;	20%	were	from	
the	 pharmaceutical	 industry;	 and	 8%	 represented	 patient	 advo-
cacy	groups.	A	videocast	of	the	proceedings	was	archived	at	the	
NHLBI	and	is	available	for	public	viewing.29,30
3.1 | Working Group 1: scientific priorities and 
innovative implementation strategies for FVIII 
inhibitor clinical trials
Co‐chaired	by	Margaret	Ragni,	MD,	MPH	and	Lindsey	George,	MD,	
Working	Group	1	was	charged	with	ascertaining	the	scientific	pri-
orities	 for	 investigator‐initiated	 clinical	 trials	 to	 include	 the	 opti-
mal	 integration	of	non‐intravenous,	non‐factor	novel	 therapeutics	
including	 gene	 therapy	 into	 the	 standard	 of	 care	 for	 PWHA	with	
inhibitors	(Table	1).	The	expanded	goals	established	for	this	group	
focused	on	the	optimization	of	both	clinical	trial	design	and	national	
infrastructure	requirements	to	increase	the	feasibility	of	a	national	
clinical	trial	agenda.31
3.2 | Working Group 2: scientific priorities and 
strategies for 21st‐century data and specimen 
collection and observational FVIII inhibitor 
cohort studies
Working	Group	2	was	co‐chaired	by	Barbara	Konkle,	MD	and	Mike	
Recht,	MD,	PhD.	This	group	was	charged	with	establishing	the	sci-
entific	priorities	for	21st‐century	data	science	and	biospecimen	col-
lection.	Design	parameters	include	prospective	cohorts	to	ascertain	
comparative	 short	 and	medium‐term	outcomes	 from	 the	 incorpo-
ration,	 or	 not,	 of	 non‐intravenous,	 non‐factor	 novel	 therapeutics,	
including	 gene	 therapy,	 into	 the	 standard	 of	 care	 for	 FVIII	 inhibi-
tors	(Table	2).	The	goals	for	this	group	focused	on	overcoming	the	
challenges	 associated	 with	 developing	 and	 maintaining	 data	 and	
biospecimen	 repositories	and	 included	deliberations	about	 the	 in-
frastructure	requirements	for	creating	a	data	and	biospecimen	re-
pository	as	well	 as	 strategies	 for	 implementation	of	 a	platform	 to	
establish	this	cohort.32
3.3 | Working Group 3: scientific priorities and 
implementation strategies for acquiring an actionable 
understanding of FVIII immunogenicity and the 
immunology of both the host immune 
response and tolerance
Co‐chaired	 by	 Shannon	 Meeks,	 MD	 and	 Roland	 Herzog,	 PhD,	
Working	Group	 3	was	 charged	with	 developing	 the	 scientific	 pri-
orities	 for	 acquiring	 an	 actionable	 understanding	 of	 FVIII	 immu-
nogenicity	 and	 the	 immunology	 of	 the	 host	 response	 and	 FVIII	
tolerance.	Such	data	can	inform	predictive	models	for	inhibitor	de-
velopment	and	novel	therapeutic	targets	(Table	3).	The	goals	of	this	
group	focused	on	the	application	of	novel	 ideas,	technologies	and	
cross‐disciplinary	science	to	these	studies.33
3.4 | Working Group 4: design of pregnancy/birth 
longitudinal cohorts that leverage omics, existing 
phenotypic data and in silico modelling to study FVIII 
immunogenicity, as well as inhibitor development and 
eradication
Working	Group	 4,	 led	 by	Deborah	Brown,	MD	 and	 Jill	 Johnsen,	
MD,	was	charged	with	designing	of	prospective	pregnancy/birth	
cohorts	 that	 leverage	 multi‐“omics”	 science,	 existing	 phenotype	
data	and	in	silico	protein	modelling	to	study	FVIII	immunogenicity,	
inhibitor	development	and	eradication	(Table	4).	The	goals	estab-
lished	for	this	group	are	also	summarized	 in	Table	4.	These	were	
primarily	 focused	on	the	design	of	data	capture	and	mechanistic	
studies,	 based	 on	 translational	 scientific	 priorities,	 required	 to	
build	 a	 personalized	medicine‐based	 clinical	 decision‐making	 al-
gorithm.	Such	an	algorithm	can	be	applied	across	the	 lifespan	to	
either	avoid	or	provoke	the	clinical	phenotype	for	the	purpose	of	
diagnosis	and/or	appropriate	time‐sensitive	intervention.34
4  | CONCLUSION
The	State	of	the	Science	Workshop	assembled	the	key	stakehold-
ers	 in	 the	 challenge	 to	 eradicate	 and	 prevent	 inhibitors:	 the	 pa-
tients,	 clinicians,	 researchers,	 federal	 government	 and	 industry.	
Through	the	commitments	of	the	Executive	Steering	Committee,	
the	Working	Group	Chairs	 and	 all	 the	members	 of	 the	Working	
Groups,	 the	many	hours	of	deliberations	 lead	 to	a	 focused	sum-
mary	 of	 scientific	 priorities	 and	 implementation	 strategies	 to	
methodically	tackle	the	challenges	of	understanding	the	immune	
response	 to	 factor	VIII	 and	 reaching	 the	 goal	 of	 eradicating	 and	
preventing	inhibitors.35
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